Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Seikagaku, Ono Ink Definitive Deal on Osteoarthritis Treatment
September 4, 2017
- Yamaha Enters Medical Field with Cell Handler, a Device to Support Drug Discovery
September 4, 2017
- Mirogabalin Delivers Positive Data for Diabetic Peripheral Neuropathic Pain: Daiichi Sankyo
September 1, 2017
- Daiichi Sankyo Ditches CL-108 Deal, Takes 27.8 Billion Yen Impaired Loss
September 1, 2017
- Daiichi Sankyo Denies Report on AZ’s Acquisition Offer
September 1, 2017
- Opdivo Clinches Batch of New Indications in South Korea
August 31, 2017
- Praluent Self-Injection Possible from Sept. 1; Repatha Auto Mini Doser Approved
August 31, 2017
- Daiichi Sankyo Share Trade Halted after Report on AZ’s Acquisition Offer
August 31, 2017
- Trerief Filed for Parkinsonism in DLB: Sumitomo Dainippon
August 31, 2017
- MSD to Cut 250 Jobs as It Foresees Portfolio Changes
August 31, 2017
- Daiichi Sankyo’s DS-8201 Gets Breakthrough Therapy Designation
August 31, 2017
- Fujifilm Holdings Aims to Achieve 500 Billion Yen in Healthcare Sales in FY2019
August 31, 2017
- Mitsubishi Tanabe Chief Looks to Tap Canaglu’s CV Outcome Data to Boost Sales
August 30, 2017
- Boston Pharma Gets Rights to Daiichi Sankyo’s Preclinical RET Inhibitor
August 30, 2017
- BMS, Daiichi Sankyo to Collaborate on Opdivo-DS-8201 Combo
August 30, 2017
- Mitsubishi Tanabe to Create New Business by Fusing LLPs with Digital Technologies
August 30, 2017
- Takeda Divesting Laboratory Animal Unit amid R&D Realignment Drive
August 29, 2017
- Suzuken Group to Shed 350 Jobs as It Seeks SGA Efficiency
August 29, 2017
- FGF23 Antibody Burosumab Filed in US: Kyowa Kirin, Ultragenyx
August 28, 2017
- Poteligeo Earns FDA’s BT Designation for CTCL: Kyowa Kirin
August 28, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…